|Bid||0.00 x 1100|
|Ask||0.00 x 3100|
|Day's Range||101.04 - 103.94|
|52 Week Range||82.81 - 116.64|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||46.44|
|Earnings Date||Jan 21, 2019 - Jan 25, 2019|
|Forward Dividend & Yield||1.48 (1.43%)|
|1y Target Est||104.80|
Mick Farrell has been the CEO of ResMed Inc (NYSE:RMD) since 2013. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that Read More...
MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.
.@ResMed to acquire @MatrixCare, expands out-of-hospital #SaaS portfolio into long-term care settings #HealthIT #skillednursing #seniorliving #homecare
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ResMed (RMD) delivered earnings and revenue surprises of 1.25% and 2.02%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had net income of 73 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 81 cents per share. The results surpassed Wall Street ...
Every investor in ResMed Inc (NYSE:RMD) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in Read More...
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
When ResMed Inc (NYSE:RMD) released its most recent earnings update (30 June 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry Read More...
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today from Medtrade the release of its new Patient Hub to personalize the patient experience and increase revenue for home medical equipment (HME) providers. Patient Hub is a patient engagement app that automates and simplifies how HME providers connect with their patients. It eliminates the need for multiple web portals and consolidates all patient interactions into one secure platform.
Nearly 2 to 1 patients prefer AirFit F30 over the current minimal-contact full face market leader
The U.S. International Trade Commission said on Friday it would investigate California-based Resmed Inc for a patent infringement complaint related to sleep apnea mask systems. The investigation is based ...
ResMed today announced it will report its first quarter of fiscal year 2019 results on Thursday, October 25, 2018, after the New York Stock Exchange market closes.
Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.
ResMed (RMD) incurred SG&A (selling, general, and administrative) expenses of $600.37 million in fiscal 2018, compared with $553.97 million in fiscal 2017. This increase was due to higher expenses related to doubtful debts and personnel for supporting commercial activities.